The UK Prospective Diabetes Study, a large clinical trial performed in 1980-90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents [REF].
Metformin has little or no effect on body weight compared with placebo in type 2 diabetes,[REF] although it causes weight loss relative to sulfonylureas, since sulfonylureas are associated with weight gain [REF].